130 related articles for article (PubMed ID: 37587857)
1. Alteration of tumor suppressors changes the endometrial tumor spectrum.
Mayo LD
EMBO Mol Med; 2023 Oct; 15(10):e18166. PubMed ID: 37587857
[TBL] [Abstract][Full Text] [Related]
2. Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition.
Cuevas IC; Sahoo SS; Kumar A; Zhang H; Westcott J; Aguilar M; Cortez JD; Sullivan SA; Xing C; Hayes DN; Brekken RA; Bae-Jump VL; Castrillon DH
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25880-25890. PubMed ID: 31772025
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of FBXW7 mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to SI-2 and dinaciclib.
Urick ME; Bell DW
Mol Carcinog; 2018 Nov; 57(11):1445-1457. PubMed ID: 29963728
[TBL] [Abstract][Full Text] [Related]
4. Proteomic profiling of FBXW7-mutant serous endometrial cancer cells reveals upregulation of PADI2, a potential therapeutic target.
Urick ME; Bell DW
Cancer Med; 2020 Jun; 9(11):3863-3874. PubMed ID: 32248654
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis.
Brown M; Leon A; Kedzierska K; Moore C; Belnoue-Davis HL; Flach S; Lydon JP; DeMayo FJ; Lewis A; Bosse T; Tomlinson I; Church DN
EMBO Mol Med; 2023 Oct; 15(10):e17094. PubMed ID: 37589076
[TBL] [Abstract][Full Text] [Related]
7. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
[TBL] [Abstract][Full Text] [Related]
8. FBXW7: a critical tumor suppressor of human cancers.
Yeh CH; Bellon M; Nicot C
Mol Cancer; 2018 Aug; 17(1):115. PubMed ID: 30086763
[TBL] [Abstract][Full Text] [Related]
9. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
[TBL] [Abstract][Full Text] [Related]
10. Recent insight into the role of FBXW7 as a tumor suppressor.
Yumimoto K; Nakayama KI
Semin Cancer Biol; 2020 Dec; 67(Pt 2):1-15. PubMed ID: 32113998
[TBL] [Abstract][Full Text] [Related]
11. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
12. High-risk endometrial cancer proteomic profiling reveals that FBXW7 mutation alters L1CAM and TGM2 protein levels.
Urick ME; Yu EJ; Bell DW
Cancer; 2021 Aug; 127(16):2905-2915. PubMed ID: 33872388
[TBL] [Abstract][Full Text] [Related]
13. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
14. Loss of Fbxw7 Impairs Development of and Induces Heterogeneous Tumor Formation in the Mouse Mammary Gland.
Onoyama I; Nakayama S; Shimizu H; Nakayama KI
Cancer Res; 2020 Dec; 80(24):5515-5530. PubMed ID: 33234509
[TBL] [Abstract][Full Text] [Related]
15. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
[TBL] [Abstract][Full Text] [Related]
16. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438
[TBL] [Abstract][Full Text] [Related]
17. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.
Allo G; Bernardini MQ; Wu RC; Shih IeM; Kalloger S; Pollett A; Gilks CB; Clarke BA
Mod Pathol; 2014 Feb; 27(2):255-61. PubMed ID: 23887303
[TBL] [Abstract][Full Text] [Related]
18. Coordination-driven FBXW7 DNAzyme-Fe nanoassembly enables a binary switch of breast cancer cell cycle checkpoint responses for enhanced ferroptosis-radiotherapy.
Yu J; Zhang Y; Li L; Xiang Y; Yao X; Zhao Y; Cai K; Li M; Li Z; Luo Z
Acta Biomater; 2023 Oct; 169():434-450. PubMed ID: 37516418
[TBL] [Abstract][Full Text] [Related]
19. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
[TBL] [Abstract][Full Text] [Related]
20. The Role of FBXW7 in Gynecologic Malignancies.
Di Fiore R; Suleiman S; Drago-Ferrante R; Subbannayya Y; Suleiman S; Vasileva-Slaveva M; Yordanov A; Pentimalli F; Giordano A; Calleja-Agius J
Cells; 2023 May; 12(10):. PubMed ID: 37408248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
